Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
My Bing
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past hour
Any time
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
BioPharma Dive
46m
BridgeBio data show sustained benefit for achondroplasia drug
Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.
Investor's Business Daily on MSN
31m
BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results
BridgeBio stock rallies on upbeat study results of a drug for a genetic disease that affects the limbs and spine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Stops concert to eject fans
Signs immigration order
Reprimanded during hearing
Call to shut down firm rejected
Reveals post-retirement plans
Juror gets $120K, dismissed
Announces new album
NJ plans to drop bald eagle
Calls Trump 'convicted felon'
To appear in Italian court
Expected to enter guilty plea
$223M to build rental homes
Home power bills to jump
Calif. construction site fire
Encampment in downtown LA
Austin visits Cambodia
Prosecutors urge to deny bid
Extradited from Ukraine
Sued by former assistant
Recalls pepperoni product
La. surgical castration option
To retire Leyland's No. 10
Reaches French Open semis
Americans shying from EVs
Testing unskippable ads
ChatGPT outage update
Collaborate to develop AI
Southwest US first heat wave
Opening statements begin
Alum donates to ISR college
Feedback